Pook D, Geynisman DM, Carles J, de Braud F, et al. A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2023 Jun 20:CCR-22-2585. doi: 10.1158/1078-0432.CCR-22-2585.
PMID: 37339186